1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the January January NightstaR Ltd A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno- Head and Neck Center Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) February Kyowa Kirin International X-Linked Hypophosphatemia Registry Children and Adolescents February Essential Medical Inc. Clinical Research Institute HUCH Post-Market Clinical Registry to Evaluate the Safety and Performance of MANTA Vascular Closure Device Under Real World Conditions in the European Union Heart and Lung Center February March March Chordate Medical AB A clinical investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the treatment of Non Allergic Head and Neck Center Rhinitis (KOSNAR) March X Santen Ciclosporin 1 mg/ml eye drop emulsion (Ikervis ) for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes: Clinical effectivness, tolerability and safety in a real world setting. HUCH Head and Neck Center March March Alnylam Pharmaceuticals Inc. ALN-ASI-003 A Phase 3 Randomized, Double-blind, Placebocontrolled Multicenter with an Open-label Etension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias Internal Medicine and Rehabilitation April
1. 2. The is Clinical Research Institute HUCH Sponsor May Oulu Univeristy Full name of the Assessment of brain dysfunction in intensive care patients by analyzing propofol-induced EEG changes Hospital clinic where the is Perioperative, Intensive Care an Pain Medicine details of the May May Aarhus University Hospital/Institute of Clinical Medicine Aarhus University Hospital May Bristol-Myers Squibb May Deciphera Pharmaceuticals, LLC May Novo Nordisk Farma Oy June F Hoffmann-La Roche Limited NOR-GRASPALL Single-Arm PK/PD and safety study of GRASPA for patients with hypersensitivity to PEG-Asparaginase, diagnosed with Ph(-) Acute Lymphoblastic Leukemia A Randomized, Double-Blind Phase 2/3 of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma A Phase 3, InterVentional, Double-Blind, Placebo Controlled to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced Gastrointestinal Stromal Tumors who have Received Treatment with Prior Anticancer Therapies Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer Immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy Children and Adolescents Comprehensive Cancer Center Comprehensive Cancer Center Abdominal Center Comprehensive Cancer Center
1. 2. The is June Sponsor F Hoffmann-La Roche Limited Full name of the A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolzumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer Hospital clinic where the is Comprehensive Cancer Center details of the
1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the
1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the
1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the
1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the
1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the